Banking on speedy domestic clinical progress and low costs, Chinese developers of innovative drugs for rare diseases are calling time on the rarity of their go-global breakthroughs.
Key Takeaways
-
Chinese players in the rare disease space are venturing out of their home turf to advance assets into clinical studies worldwide, especially in the US.
Over the past few years, while Chinese-made novel drugs for various cancers have successfully landed in major international markets, including...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

